Search Results - "Myers, K N"

Patient and physician factors associated with participation in cervical and uterine cancer trials: An NRG/GOG247 study by Brooks, Sandra E, Carter, Randy L, Plaxe, Steven C, Basen-Engquist, Karen M, Rodriguez, Michael, Kauderer, James, Walker, Joan L, Myers, Tashanna K.N, Drake, Janet G, Havrilesky, Laura J, Van Le, Linda, Landrum, Lisa M, Brown, Carol L

“…Abstract Purpose The aim of this study was to identify patient and physician factors related to enrollment onto Gynecologic Oncology Group (GOG) trials…”
Get full text

MRNIP is a replication fork protection factor by Bennett, L G, Wilkie, A M, Antonopoulou, E, Ceppi, I, Sanchez, A, Vernon, E G, Gamble, A, Myers, K N, Collis, S J, Cejka, P, Staples, C J

“…The remodeling of stalled replication forks to form four-way DNA junctions is an important component of the replication stress response. Nascent DNA at the…”
Get full text

Stage IVB endometrial cancer: Does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis by Landrum, Lisa M, Moore, Kathleen N, Myers, Tashanna K.N, Lanneau, Grainger S, McMeekin, D. Scott, Walker, Joan L, Gold, Michael A

“…Abstract Objective The pattern of metastasis for Stage IV endometrial carcinoma (EC) is similar to that for ovarian carcinoma (OC), hence the goal of surgical…”
Get full text

Ovarian cancer in the octogenarian: Does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply? by Moore, Kathleen N, Reid, Monica S, Fong, Daniel N, Myers, Tashanna K.N, Landrum, Lisa M, Moxley, Katherine M, Walker, Joan L, McMeekin, D. Scott, Mannel, Robert S

“…Abstract Objective The cornerstone of therapy for advanced ovarian cancer is cytoreductive surgery (CRS) followed by platinum based chemotherapy. Optimal…”
Get full text

Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: A review of complications and completion rates by Landrum, Lisa M, Gold, Michael A, Moore, Kathleen N, Myers, Tashanna K.N, McMeekin, D.S, Walker, Joan L

“…Abstract Objective. Intraperitoneal (IP) chemotherapy has a clear survival advantage in patients with advanced ovarian cancer, but the high rate of…”
Get full text

A Biomechanically Based Observational Tennis Serve Analysis Method is Reliable and Valid by Myers, N K, Kibler, W B, Uhl, T L

“…An abstract of a study by Myers and Kibler determining the inter-observer reliability of an observational tennis serve analysis (OTSA) tool and investigating…”
Get full text

GLORIOSA: A randomized, open-label, phase 3 study of mirvetuximab soravtansine with bevacizumab vs. bevacizumab as maintenance in platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer by O'Malley, David M., Myers, Tashanna K. N., Zamagni, Claudio, Diver, Elisabeth, Lorusso, Domenica

“…TPS5622 Background: Elevated folate receptor-alpha (FRα) expression is a characteristic of epithelial ovarian cancer (EOC), thereby providing a rational target…”
Get full text

Evaluation of Xenopus tropicalis as an Alternative Test Organism for Frog Embryo Teratogenesis Assay-Xenopus (FETAX) by Ok Song, Min, Fort, Douglas J., McLaughlin, Daniel L., Rogers, Robert L., Thomas, John H., Buzzard, Brody O., Noll, Andra M., Myers, Natalie K.

“…Abstract As a formal recommendation from an Interagency Coordinating Committee for the Validation of Alternative Methods (ICCVAM) workshop review of the Frog…”
Get full text

Racial disparities and survival outcome of patients with locally advanced cervix cancer in the international randomised phase 3 OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274) by Lee, Yeh Chen, Castellano, Tara, Myers, Tashanna K. N., Barnes, Elizabeth H, Chase, Dana Meredith, McCormick, Colleen, Diamante, Katrina, Shannon, Catherine M., Huh, Warner King, Lea, Jayanthi Sivasothy, Walker, Joan L., Small, William, Miller, Katherine, Govindarajulu, Geetha, Monk, Bradley J., Stockler, Martin R, Moore, Kathleen N., Mileshkin, Linda R., Bae-Jump, Victoria Lin

“…1594 Background: OUTBACK was an international multi-center phase 3 trial investigating adjuvant chemotherapy following definitive chemoradiation in locally…”
Get full text

Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression by Moore, Kathleen N., Angelergues, Antoine, Konecny, Gottfried E., Banerjee, Susana N., Pignata, Sandro, Colombo, Nicoletta, Moroney, John William, Cosgrove, Casey, Lee, Jung-Yun, Roszak, Andrzej, Breuer, Shani, Tromp, Jacqueline Maria, Bello-Roufai, Diana, Gilbert, Lucy, Miller, Rowan, Myers, Tashanna K. N., Wang, Yuemei, Berkenblit, Anna, Lorusso, Domenica, Van Gorp, Toon

“…LBA5507 Background: Mirvetuximab soravtansine (MIRV), an antibody drug conjugate targeting FRα, demonstrated clinically meaningful antitumor activity in a…”
Get full text

ROCC/GOG-3043: A randomized non-inferiority trial of robotic versus open radical hysterectomy for early-stage cervical cancer by Bixel, Kristin Leigh, Leitao, Mario M., Chase, Dana Meredith, Quick, Allison, Lim, Peter C, Eskander, Ramez Nassef, Gotlieb, Walter H., LoCoco, Salvatore, Martino, Martin A, McCormick, Colleen, Myers, Tashanna K. N., Tewari, Krishnansu Sujata, Slomovitz, Brian M., Walker, Joan L., Copeland, Larry J., Monk, Bradley J., Randall, Leslie M.

“…TPS5605 Background: Minimally invasive surgery (MIS) is associated with improved perioperative safety outcomes, but, in 2018, the Laparoscopic Approach to…”
Get full text

A phase 3, randomized, double-blind, adaptive, placebo/paclitaxel-controlled study of AVB-S6-500 in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer (GOG-3059/ENGOT OV-66/AVB500-OC-004) by Fuh, Katherine Cynthia, Herzog, Thomas J., Moore, Kathleen N., Myers, Tashanna K. N., Rimel, BJ, Liu, Joyce F., Secord, Angeles Alvarez, Hamilton, Erika P., Reid, Thomas J., Lewin, Sharyn Nan, Mullen, Mary M, Mills, Kathryn A., Anderson, Randy, Rangwala, Reshma A.

“…Abstract only TPS5605 Background: The AXL receptor and its activating ligand, GAS6, are important drivers of metastasis and therapeutic resistance in human…”
Get full text

Ex-vivo drug screening of surgically resected glioma stem cells to replace murine avatars and provide personalise cancer therapy for glioblastoma patients [version 2; peer review: 2 approved] by Gagg, Hannah, Williams, Sophie T., Conroy, Samantha, Myers, Katie N., McGarrity-Cottrell, Connor, Jones, Callum, Helleday, Thomas, Rantala, Juha, Rominiyi, Ola, Danson, Sarah J., Collis, Spencer J., Wells, Greg

“…With diminishing returns and high clinical failure rates from traditional preclinical and animal-based drug discovery strategies, more emphasis is being placed…”
Get full text

Ex-vivo drug screening of surgically resected glioma stem cells to replace murine avatars and provide personalise cancer therapy for glioblastoma patients [version 1; peer review: 2 approved] by Gagg, Hannah, Williams, Sophie T., Conroy, Samantha, Myers, Katie N., McGarrity-Cottrell, Connor, Jones, Callum, Helleday, Thomas, Rantala, Juha, Rominiyi, Ola, Danson, Sarah J., Collis, Spencer J., Wells, Greg

“…With diminishing returns and high clinical failure rates from traditional preclinical and animal-based drug discovery strategies, more emphasis is being placed…”
Get full text

Web-based discovery and integration of archaeological historic properties inventory data: The Digital Index of North American Archaeology (DINAA) by Wells, J. J., Kansa, E. C., Kansa, S. W., Yerka, S. J., Anderson, D. G., Bissett, T. G., Myers, K. N., Carl DeMuth, R.

Get full text